Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + erlotinib with metformin versus placebo in advanced pancreatic cancer
NL-OMON34831Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic cancer (PC) comparing Gemcitabine + erlotinib + metformin with Gemcitabine + erlotinib + placebo (2 arms). Primary endpoint: Survival after 6 months. Started Jun 2010; status: active, not recruiting.
02
Drugs
metformingemcitabineerlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON34831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34831.